Effect of Efpeglenatide on Cardiovascular Outcomes
Status:
Terminated
Trial end date:
2020-12-10
Target enrollment:
Participant gender:
Summary
Primary Objective:
To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major
adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high
cardiovascular (CV) risk.
Secondary Objectives:
To demonstrate that efpeglenatide 4 and 6 mg was superior to placebo in T2DM participants
with high CV risk on the following parameters:
- 3-point MACE.
- Expanded CV outcome.
- Composite outcome of new or worsening nephropathy.
To assess the safety and tolerability of efpeglenatide 4 and 6 mg, both added to standard of
care in T2DM participants at high CV risk.